LivaNova PLC

Latest Results (09.10.2025):

LivaNova PLC reported strong financial performance for the fourth quarter and full-year of 2024, demonstrating significant revenue growth, improved earnings, and robust cash flow. The company also provided optimistic guidance for 2025, reflecting continued growth and operational excellence.

Revenue Growth

In the fourth quarter of 2024, LivaNova achieved a total net revenue of $321.8 million, marking a 3.8% increase on a reported basis and a 6.8% growth on an organic basis compared to the same period in the previous year. For the full year, revenue reached $1.25 billion, up by 8.7% on a reported basis and 10.7% on an organic basis.

Earnings Per Share

Fourth-quarter diluted earnings per share (EPS) on a U.S. GAAP basis were $1.02, up from $0.30 in Q4 2023. Adjusted diluted EPS for the quarter stood at $0.81. For the full year 2024, diluted EPS was $1.16 on a U.S. GAAP basis and $3.38 on an adjusted basis, both showing substantial growth from the previous year.

Cash Flow

Full-year 2024 net cash provided by operating activities was $183.0 million, with an adjusted free cash flow of $162.9 million, highlighting the company’s strong cash generation capabilities.

Guidance for 2025

LivaNova expects full-year 2025 revenue to grow between 5.0% and 6.0% on a constant-currency basis and between 6.0% and 7.0% on an organic basis. The company also forecasts adjusted diluted earnings per share to range from $3.65 to $3.75 and anticipates adjusted free cash flow between $135 million and $155 million.

Clinical Achievements

The company announced positive outcomes from the OSPREY clinical study for moderate-to-severe obstructive sleep apnea, meeting its primary safety and efficacy endpoints. Additionally, pivotal articles from the RECOVER clinical study on treatment-resistant depression demonstrated meaningful therapeutic effects of VNS Therapy™.

Leadership Updates

In January 2025, Natalia Kozmina was appointed as Chief Human Resources Officer, reinforcing LivaNova’s commitment to talent and operational excellence.